search button
Open Access

Heat shock protein 20 suppresses breast carcinogenesis by inhibiting the MAPK and AKT signaling pathways

  • Authors:
    • Yinxi Yang
    • Yifeng Wu
    • Lihong Hou
    • Xin Ge
    • Guoquan Song
    • Hongdou Jin

  • View Affiliations

  • Published online on: November 3, 2022     https://doi.org/10.3892/ol.2022.13582
  • Article Number: 462

  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Heat shock protein (HSP) 20 belongs to the small HSP family and exhibits diverse functions, including tumor suppression, in addition to being a molecular chaperon, which is the classical property of HSPs. The present study aimed to examine the association between HSP20 expression and breast cancer (BC) progression in patients, and to explore the possible role of HSP20 in malignant phenotypes of BC cells. A series of experiments, including reverse transcription‑quantitative PCR, western blotting, Cell Counting Kit‑8 and flow cytometry, were performed. Data from Gene Expression Omnibus and Kaplan‑Meier Plotter revealed that HSP20 expression was significantly downregulated in BC tissues, and patients with BC with lower HSP20 expression exhibited poorer recurrence‑free survival. The data revealed that HSP20 was closely associated with the pathological tumor stage (P=0.015) and pathological tumor node metastasis (P=0.031) of patients with BC. Additionally, HSP20 expression was markedly decreased in BC cell lines. Exogenous overexpression of HSP20 inhibited proliferation and accelerated apoptosis of BC cells. These cells exhibited decreased migration and invasion when HSP20 was overexpressed. Furthermore, HSP20 overexpression suppressed the MAPK and AKT signaling pathways, as evidenced by the reduced phosphorylation levels of AKT, ERK, JNK and p38. Knockdown of HSP20 exerted the opposite effects. Notably, the AKT agonist, SC79, and the ERK agonist, LM22B‑10, reversed the decrease in cell proliferation and migration induced by HSP20 overexpression. Overall, the data suggest that the decreased expression of HSP20 in BC tissues may be associated with disease progression. HSP20 also attenuated the malignant phenotype of BC cells and the inhibition of MAPK and AKT signaling may be associated with this effect. Therefore, HSP20 may be a potential prognostic marker or a candidate therapeutic target for BC.
View Figures
View References

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Wu Y, Hou L, Ge X, Song G and Jin H: Heat shock protein 20 suppresses breast carcinogenesis by inhibiting the MAPK and AKT signaling pathways. Oncol Lett 24: 462, 2022
APA
Yang, Y., Wu, Y., Hou, L., Ge, X., Song, G., & Jin, H. (2022). Heat shock protein 20 suppresses breast carcinogenesis by inhibiting the MAPK and AKT signaling pathways. Oncology Letters, 24, 462. https://doi.org/10.3892/ol.2022.13582
MLA
Yang, Y., Wu, Y., Hou, L., Ge, X., Song, G., Jin, H."Heat shock protein 20 suppresses breast carcinogenesis by inhibiting the MAPK and AKT signaling pathways". Oncology Letters 24.6 (2022): 462.
Chicago
Yang, Y., Wu, Y., Hou, L., Ge, X., Song, G., Jin, H."Heat shock protein 20 suppresses breast carcinogenesis by inhibiting the MAPK and AKT signaling pathways". Oncology Letters 24, no. 6 (2022): 462. https://doi.org/10.3892/ol.2022.13582